Diovan CHF Claim: Use As Substitute For ACE Inhibitor Supported By FDA

FDA's "approvable" letter for Diovan in congestive heart failure suggests that existing data are sufficient to approve the drug as a substitute to ACE inhibitors, Novartis Pharmaceuticals Development Head Joerg Reinhardt told an Oct. 30 New York analysts meeting